The Research Conundrum: Where Next For Cancer and the Immune System? – Bristol-Myers Squibb sponsored session

12:50 pm-1:50 pm

Room: Boisdale

Programme stream(s): Treatment
Programme session type(s): Sponsored session

Speaker: Poulam Patel, University of Nottingham
Speaker: Gary Middleton, University of Birmingham
Sponsored by:
Bristol-Myers Squibb

This session is sponsored by Bristol-Myers Squibb.

The complex interactions between the immune system and cancer have been a focus
of research for many years. In the past two decades, armed with innovative research
tools and techniques, our understanding of immunotherapy and cancer has improved
substantially. We have seen the effect immunotherapy can have on the survival of
some cancer patients, but there is still work to be done. Numerous immunological
targets are under evaluation for various types of cancer; our understanding is also
growing in terms of how the immune system may function differently in different
tumour types or molecular subtypes of cancer, at different disease stages, and before
and after treatment. This appreciation of the heterogeneity of cancer has highlighted
opportunities to make cancer treatment more precise and personalised, so the right
treatment is given to the right patient at the right time.

At this symposium, Professor Poulam Patel (University of Nottingham) will review the
role of the immune system in cancer and the opportunities to exploit it, exploring the
rationale for targeting specific immune molecules and pathways. Professor Gary
Middleton (University of Birmingham) will discuss how precision medicine is being
incorporated into clinical research and the subsequent implications for trial design.
Looking to the future, he will consider how research approaches need to evolve so
advances for cancer patients can continue.